{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.470","upperLimit":"0.764","value":"0.617"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"}],"units":"Participants"}],"description":"Kaplan-Meier method was used to estimate the EFS of patients with osteosarcoma treated with chemotherapy and Bevacizumab.","dispersionType":"95% Confidence Interval","groups":[{"description":"All the 42 evaluable participants in this study had osteosarcoma, of which 22 had events and 20 had no event.","id":"OG000","title":"All Participants"}],"paramType":"NUMBER","populationDescription":"All the 42 evaluable participants were included in this analysis.","reportingStatus":"POSTED","timeFrame":"After all patients have completed therapy, up to 2 years after last patient is enrolled","title":"2-Year Event Free Survival (EFS) of Patients With Osteosarcoma","type":"SECONDARY","unitOfMeasure":"probability"}